Health Condition 1: null- Oropharyngeal Candidiasis
Conditions
Interventions
Intervention1: Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories , India): 10mg troche 5 times a day for 14 consecutive days
Control Intervention1: Clotrimazole Troche/Lozen
Sponsors
THINQ Pharma CRO Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Presence of specific signs and symptoms of Oropharyngeal Candidiasis, including erythematous areas, white patches(thrush), mouth pain, irritation, burning, glossitis, altered taste, pruritis, dysphagia and odynophagia. 2. Clinical examination of oropharynx consistent with a diagnosis of oral candidiasis (such as creamy, white, curd-like patches of “thrush ? or erythematous lesions on mucosal surfaces). 3. Confirmation of Candidiasis by findings on direct microscopic examination (potassium hydroxide smear) consistent with Candida species or positive fungal culture for Candida species, with culture obtained in the 2 days preceding initiation of therapy with the study drug. 4. Subjects who are able and willing to give Informed Consent.
Exclusion criteria
Exclusion criteria: 1. Female subjects who are pregnant, lactating or planning to become pregnant during the study period. 2. Subjects diagnosed with disseminated candidiasis or requiring systemic antifungal therapy. 3. Subjects diagnosed with hairy leukoplakia. 4. Presence of only perioral lesions, e.g., angular chelitis. 5. History of intolerance or sensitivity to clotrimazole (or other imidazole or azole compounds) or any constituent of Roxane ® or the generic Clotrimazole Troche/ Lozenges or unable to tolerate oral medication. 6. Subjects having history of resistance to treatment with clotrimazole (Subject who are resistant to clotrimazole after culture and sensitivity test have to be excluded from the study). 7. Subjects who have received any oral or systemic antifungal therapy within fourteen (14) days prior to randomization. 8. Subjects who have received any investigational therapy within 30 days prior to randomization. 9. Subjects who have been diagnosed with any concomitant condition that, in the opinion of the investigator, could interfere with the evaluation of efficacy or safety, or would make it unlikely that the subject would complete the study. 10. Subjects who have been treated with protease inhibitors for the first time within 30 days. 11. Subjects who have been taking medications known to have significant interaction with azoles (e.g., antacids, H2-receptor blockers, rifampin, phenytoin, carbamazepine, astemizole). 12. Subjects who have a history of candidal prophylaxis with any azole antifungal medication. 13. Any subject with recurrent Oropharyngeal Candidiasis. 14. Any subject who is chronically infected with Candida. 15. Any subject with baseline liver function tests greater than 3 times the upper limit of normal (ULN). 16. CD4 cell count less than 200 cells/mm3. 17. Absolute neutrophil count less than 500/mm3. 18. Subject with history of Type II Diabetes Mellitus with Uncontrolled Blood Sugar levels. (I.e. Random Blood Sugar level > 350). 19. Suspected inability (or) unwillingness to comply with the study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical cure i.e., complete resolution of all signs and symptoms of Oropharyngeal CandidiasisTimepoint: Day 17-25 | — |
Secondary
| Measure | Time frame |
|---|---|
| Mycological cure (negative culture and negative KOH for Candida species)Timepoint: Day 15-17 | — |
Countries
India
Contacts
Public ContactDr Neeta Nargundkar
THINQ Pharma-CRO Ltd
Outcome results
None listed